Introduction: Low-dose computed tomography (LDCT) lung cancer screening is recommended in the United States. While new solid nodules after baseline screening have a high lung cancer probability at small size and require lower size cutoff values than baseline nodules, there only is limited evidence on management of new subsolid nodules.
Results: In the three incidence screening rounds, 60 new subsolid nodules (43 [72%] part-solid, 17 [28%] nonsolid) not visible in retrospect were detected in 51 participants, representing 0.7% (51 of 7295) of participants with at least one incidence screening. Eventually, 6% (3 of 51) of participants with a new subsolid nodule were diagnosed with (pre-)malignancy in such a nodule. All (pre-)malignancies were adenocarcinoma (in situ) and diagnostic workup (referral 950, 364, and 366 days after first detection, respectively) showed favorable staging (stage I). Overall, 67% (33 of 49) of subsolid nodules with an additional follow-up screening were resolving.
Conclusions: Less than 1% of participants in LDCT lung cancer screening presents with a new subsolid nodule after baseline. Contrary to new solid nodules, data suggest that new subsolid nodules may not require a more aggressive follow-up.
Introduction
Lung cancer screening is recommended in the United States, whereas European stakeholders are in anticipation of the final results of the randomized-controlled DutchBelgian Lung Cancer Screening Trial (NELSON).
1-3 A central challenge in low-dose computed tomography (LDCT) lung cancer screening is the identification of clinically relevant lung cancer while preventing overdiagnosis and overtreatment. 4 Subsolid nodules are particularly challenging as they carry a relatively high malignancy rate but possess a slow growth rate. Current (clinical) guidelines propose a watchful waiting approach with computed tomographic surveillance. 5, 6 Nodules found at baseline screening and new nodules thereafter must be differentiated because they develop within different timeframes. Recently, it was shown that new solid nodules have a high lung cancer risk at small size and require lower size cutoff values than baseline nodules, which was adopted in a European position statement on lung cancer screening. 1, 7 A subsequent analysis of new solid nodules in the National Lung Screening Trial provided similar findings. However, currently, there is only limited evidence on management of new subsolid nodules. [9] [10] [11] The aim of this study was to assess the occurrence, characteristics, and lung cancer probability of subsolid nodules detected in incidence screening rounds of the NELSON trial.
Material and Methods
The NELSON trial (trial registration number, ISRCTN63545820) was authorized by the Dutch Health Care Committee and approved by Ethics Committees of all participating centers in the Netherlands and Belgium. The recruitment process and study design have been previously published. 12, 13 Summarized, eligible patients were adults aged 50 to 75 years, who had smoked more than 15 cigarettes per day for more than 25 years or 10 cigarettes per day for more than 30 years, and were still smoking or stopped smoking less than 10 years previously. Although the final results of the NELSON trial have not been released yet, most participants are likely White. Participants with subsolid nodules detected in the three incidence screening rounds and registered as new or previously below the trial's detection limit were assessed.
A nodule was classified as (pre-)malignancy when it was diagnosed as lung cancer during diagnostic workup according to national and international guidelines including histologic assessment. Nodules were classified as benign when either the nodule was benign at histologic examination or diagnostic evaluation had a negative finding. A nodule was also considered benign if it was ruled negative during the participant's last followup screening of the NELSON trial and the participant did not present with post-screening lung cancer according to the Dutch and Belgian national cancer registries and medical file review. 14 
Statistical Analysis
Continuous variables are presented as median and interquartile range (IQR) and categorical variables are presented as frequencies and respective percentages. Confidence intervals of proportions were calculated using the Agresti-Coull method. Nominal variables were analyzed with Fisher's exact test. Statistical significance was considered for p < 0.05 and all tests were 2-tailed. Statistical analysis was performed with SPSS version 25.0 (IBM, Armonk, NY) and R (version 3.3.3).
Results
Within the three incidence rounds of the NELSON trial, 79 new subsolid nodules were detected in 67 participants (0.9% [67 of 7295] of participants with at least one incidence screening). After exclusion of 16 subsolid nodules that were visible in retrospect according to the NELSON radiologists (31% [5 of 16] (pre-) malignancies: four adenocarcinoma in situ and one adenocarcinoma stage IA), two new subsolid nodules from one participant who also had baseline nodules because the eventual diagnosis (adenocarcinoma in situ) could not be matched unequivocally to a nodule, and one new subsolid nodule because it was a renal cell carcinoma metastasis, a total of 60 new subsolid nodules in 51 participants (0.7% [51 of 7295] of participants with at least one incidence screening) were included in the final analysis (Fig. 1) .
The median baseline age of these participants was 59 years (IQR: 54 to 63 years), 82% (42 of 51) were men, and median smoking pack-years at baseline was 39 (IQR: 31 to 49 pack-years). In total, 25% (15 of 60) of new subsolid nodules were detected in the second screening round (1 year after baseline), 50% (30 of 60) in the third screening round (3 years after baseline), and 25% (15 of 60) in the fourth screening round (5.5 years after baseline). Characteristics of new subsolid nodules and (pre-)malignancy occurrence stratified by subsolid nodule type are presented in Table 1 . Eventually, 6% (3 of 51) of participants with a new subsolid nodule had a (pre-)malignancy diagnosed in such a nodule (Table 2) .
After initial detection of a new subsolid nodule, 86% (44 of 51) of participants received an additional screening in the NELSON trial (1 ended screening and 6 were referred immediately for diagnostic workup). On first follow-up after initial detection, 33% (16 of 49) of subsolid nodules had persisted. The median time until first follow-up was 51 days (IQR: 47 to 87 days).
For both nonresolving and resolving nodules, the first follow-up primarily took place within 90 days after initial detection (81% and 82%, respectively).
Of the nonresolving subsolid nodules, 75% (12 of 16) were in the upper lung and 19% (3 of 16) were (pre-)malignant.
1,563 noncalcified new (sub)solid nodules in 997 parƟcipants detected during the three incidence screening rounds 79 noncalcified new subsolid nodules in 67 parƟcipants 60 noncalcified new subsolid nodules in 51 parƟcipants were included in the final analysis 1,484 new solid nodules from 949 parƟcipants were excluded. 16 new nodules from 15 parƟcipants were excluded because they were visible in retrospect below the trial's detecƟon limit (15mm³) according to the NELSON radiologists. Of these nodules, 31% (5/16) were a (pre-)malignancy (4 adenocarcinoma in situ, 1 adenocarcinoma stage IA).
2 new subsolid nodules from 1 parƟcipant with also baseline nodules were excluded because the parƟcipant's eventual diagnosis (adenocarcinoma in situ) could not be matched to any nodule unequivocally.
1 new subsolid nodule from 1 parƟcipant was excluded because it was a renal cell carcinoma metastasis. 
Discussion
This study focused on new subsolid nodules detected in the incidence screening rounds of the NELSON trial. Until now, there are limited data concerning new subsolid nodules detected in low-dose computed tomography lung cancer screening trials. We report four major findings. First, new subsolid nodules were found in less than 1% of participants with at least one screening after baseline. Second, only 33% of subsolid nodules with an additional screening after detection persisted until first follow-up. Third, 6% of participants with a new subsolid nodule were diagnosed with a (pre-)malignancy in such a nodule, with 19% of the persistent new subsolid nodules being identified as (pre-)malignant lesions. Fourth, new subsolid (pre-)malignancies were adenocarcinoma (in situ) and diagnostic workup (referral 950, 364, and 366 days after first detection, respectively) showed favorable staging (stage I).
Our study shows that the occurrence of new subsolid nodules is low in a lung cancer screening program and that the lung cancer stage is favorable even with referral after 1 year. This is comparable to findings of the I-ELCAP trial, where less than 1% of participants presented with new part-solid or new nonsolid nodules, respectively, and all lung cancer cases were stage I. 9, 10 Similarly, previous prospective studies from Japan indicated the conservative nature of subsolid nodules with all pathologically confirmed tumors being stage I and 1% of subsolid nodules being invasive adenocarcinomas. 15, 16 Additionally, an analysis of lung cancer manifesting as nonsolid nodule in the National Lung Screening Trial concluded that annual follow-up is appropriate. 17 Furthermore, as also shown in this study, a large proportion of new subsolid nodules resolve until first follow-up, which is comparable to previous reports where 40% to 70% of subsolid nodules were transient. 18, 19 New subsolid nodules that persist may require additional screening or referral for diagnostic workup with 19% being (pre-)malignant.
Considering the presented data and results of the I-ELCAP trial, 9, 10 there is no indication that new subsolid nodules detected after baseline require a more aggressive follow-up than baseline subsolid nodules. This contrasts findings for new solid nodules which have a high lung cancer risk even at small size, necessitating adapted cutoffs. 7 This study has limitations. Although the NELSON study is the second largest lung cancer screening trial, the number of new subsolid nodules was limited. The precise malignancy rate remains unknown because a part of the nonresolving subsolid nodules were not resected. Although these nodules were not diagnosed as interval lung cancer, the final survival rates of the NELSON trial are not yet available.
In conclusion, new subsolid nodules after baseline are rare and often resolve during follow-up. Lung cancer found in new subsolid nodules presents with favorable stage. Considering the existing data, a more aggressive follow-up for new subsolid nodules than for baseline subsolid nodules seems unwarranted.
